With this background in mind, to further elucidate the molecular mechanisms by which CV can ameliorate autistic disorder in this paper, C57BL mice were injected with valproic acid and treated for 40 days with 200 mg/kg of CV, and the TLR4/NF‐κB pathways were evaluated. The gene discussed is TLR4; the disease is autism.